Microdosing Ketamine: The Rise of Low-Dose At-Home Treatment

In-clinic ketamine infusions can cost $400-$800 per session. A full initial course runs several thousand dollars. Enter the low-dose at-home model — sometimes called "microdosing ketamine" — which has exploded in popularity since 2022, bringing treatment costs down to $129-$300/month.

What "Microdosing Ketamine" Actually Means

Standard IV infusion uses ~0.5 mg/kg (~35 mg for an average adult). Standard sublingual lozenges use 100-400 mg. Low-dose "microdose" protocols use 5-30 mg sublingually. At the low end (5-15 mg), most patients report little to no perceptual changes — no dissociation, no impairment. The terminology is borrowed from psychedelic culture; technically, most protocols are better described as "low-dose" rather than true microdosing.

The Joyous Model: Ketamine at $129/Month

Joyous has become the most visible player in the low-dose space. Their approach: online assessment, licensed prescriber review, compounded ketamine sublingual tablets prescribed at very low starting doses with daily titration, daily mood check-ins via app, and a monthly cost of $129. Key differences from traditional therapy: daily dosing (vs. periodic sessions), dose titration based on patient feedback, and minimal to no dissociative effects.

Clinical Evidence

Joyous published internal data on 10,000+ patients showing 73% reported depression improvement at a median effective dose of ~15 mg/day. Independent research on low-dose oral ketamine shows antidepressant effects, but no large placebo-controlled RCTs exist specifically for the daily 5-15 mg sublingual protocol. The evidence base supports low-dose ketamine broadly, but the specific daily micro-dosing protocol is ahead of published research.

Who Is Low-Dose At-Home Ketamine For?

Good candidates:

• People priced out of in-clinic treatment ($400-$800/session)
• Those seeking a less intense experience without dissociative effects
• Patients who've responded to IV ketamine and want a lower-cost maintenance option
• Those in areas without ketamine clinics

Safety Considerations

At-home ketamine raises important safety considerations:

• No real-time medical monitoring of blood pressure or heart rate
• Self-administration of Schedule III controlled substance carries diversion risk
• Variable sublingual absorption (25-30% bioavailability) creates dose variability
• Quality of telehealth oversight varies widely — some providers are rigorous, others are minimal